List of Studies ( Metabolite:11Z-Eicosaenoyl-EA)
Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Units(range) |
---|---|---|---|---|---|---|---|
ST000509 | AN000780 | Metabolic changes to maternal rat liver tissue during and post-pregnancy | Liver | Rat | University of Colorado, Denver | Arbitrary units | |
ST001788 | AN002899 | β-Adrenergic regulation of metabolism in macrophages (part-IV) | Macrophages | Human | Monash University | Intensity | |
ST000310 | AN000490 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | Peak area |
ST002182 | AN003574 | Amelioration of developmental programming of NAFLD in weanling liver using PQQ | Liver | Mouse | Fatty liver disease | University of Oklahoma Health Sciences Center | Peak area |
ST002191 | AN003586 | Amelioration of developmental programming of NAFLD in fetal liver using PQQ | Liver | Mouse | Fatty liver disease | University of Oklahoma Health Sciences Center | Peak area |
ST000310 | AN000492 | TC and B6 untreated plasma in lupus-prone mice lipidomics (part-II) | Blood | Mouse | Lupus | University of Florida | Peak height |
ST001274 | AN002115 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-I) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST001275 | AN002116 | Metabolomics-based profiling of the mode of action of Pathogen Box compounds in Trypanosoma brucei (part-II) | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST001276 | AN002117 | Development and Characterisation of a Novel Class of Aroyl Guanidine Containing Anti-Trypanosomal Compounds | Cultured cells | Trypanosoma brucei | Sleeping sickness | Monash University | Peak height |
ST000422 | AN000669 | Type 1 Diabetes good glycemic control and controls samples | Blood | Human | Diabetes | Mayo Clinic | Peak intensity |
ST002094 | AN003420 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |
ST002094 | AN003421 | Commensal intestinal microbiota regulates host luminal proteolytic activity and intestinal barrier integrity through β-glucuronidase activity (Part 1) | Feces | Human | Irritable bowel syndrome | Mayo Clinic | raw intensity |